Status:

COMPLETED

Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

Lead Sponsor:

Currax Pharmaceuticals

Conditions:

Obesity

Eligibility:

All Genders

18+ years

Brief Summary

The fixed-dose combination of naltrexone 8mg and bupropion 90mg extended-release oral tablet is marketed under the trade name CONTRAVE® in the U.S. In this protocol, the investigators propose to gener...

Detailed Description

The study will assess whether patients who initiate treatment with NB are at an elevated risk of MACE compared with patients who initiated treatment with lorcaserin, an active comparator chosen to red...

Eligibility Criteria

Inclusion

  • For the main objective (1.0, 1.1), patients are eligible if they meet the following Inclusion Criteria:
  • Have at least one prescription for NB between September 2014 and February 2020, including concurrent prescriptions (within 15 days) for naltrexone and bupropion; or have at least one prescription for lorcaserin;
  • Have at least 180 days of data available prior to cohort entry with no evidence of prescriptions or dispensings of NB or lorcaserin;
  • Have at least one BMI value available in the 180 days prior to cohort entry, inclusive of the index date;
  • Have documentation of at least one outpatient medical visit 180 or more days prior to cohort entry, and at least one healthcare interaction in the 180 days prior to cohort entry;
  • Are at least 18 years of age on the cohort entry date.
  • For the main objective, patients are not eligible if they have a diagnosis of any of the following conditions in the 180 days before the cohort entry date:
  • Epilepsy;
  • Bulimia;
  • Anorexia nervosa;
  • Surgical procedure for weight loss.

Exclusion

    Key Trial Info

    Start Date :

    September 1 2014

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2022

    Estimated Enrollment :

    31889 Patients enrolled

    Trial Details

    Trial ID

    NCT06090461

    Start Date

    September 1 2014

    End Date

    December 1 2022

    Last Update

    June 25 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Currax Pharmaceuticals

    Brentwood, Tennessee, United States, 37027